Daily Archives: October 30, 2014

Irvine Pharmaceutical Services Announces the Opening of an Analytical Facility in Hangzhou, China

IRVINE, Calif., Oct. 30, 2014 /PRNewswire/ — Irvine Pharmaceutical Services, Inc., a leading provider in cGMP contract development and parenteral manufacturing services, announces plans to open a new facility in Hangzhou, China. This 115,000sqft. newly built, state-of-the-art facility will expand Irvine’s service offerings into the Asian markets.

Irvine’s newest facility is scheduled to be fully operational in the first quarter of 2015. CEO and Founder, Dr. Assad J. Kazeminy explains, “Irvine is responding to the rising needs of large multi-national pharmaceutical companies that are looking for contract organizations overseas that include robust cGMP quality infrastructure and technical expertise. Irvine will now have a local presence and a strong understanding of the local market to offer the region high quality analytical support.”

Learn more about Irvine’s expansion into the Asian market – Visit us at booth 3110 at the 2014 AAPS Annual Meeting and Exposition in San Diego, CA on November 2 – 6, 2014.

About Irvine

Irvine Pharmaceutical Service Inc. is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine provides cGMP contract development and manufacturing services such as parenteral manufacturing (liquid and lyophilized), preformulation/formulation development, analytical development, biopharmaceutical development, stability storage, analytical chemistry, structural chemistry, microbiology, and drug delivery device testing.

Learn more at www.irvinepharma.com or call +1-949-951-4425.

Frost & Sullivan Commends Draeger’s Strategic Excellence in Offering an Extensive Solution Line for the Ventilation, Anesthesia and Monitoring Markets

– Draeger is currently working on innovative technologies that will improve the control of ventilation equipment for patients in critical care

MOUNTAIN VIEW, Calif., Oct. 30, 2014 /PRNewswire/ — Based on its recent analysis of the mechanical ventilation equipment market, Frost & Sullivan recognizes Draegerwerk AG & Co. KGaA (Draeger) with the 2014 Global Frost & Sullivan Award for Growth Excellence Leadership. Draeger’s extensive and versatile portfolio in ventilation, anesthesia, vital signs monitoring, and warming therapy products, as well as related accessories and consumables, has given it a clear edge over competitors in the critical care solutions markets. The advanced product designs cater to hospitals that value safety, ergonomics, efficiency and comfort. Furthermore, the offer of an end-to-end solution reduces the total cost of ownership of the devices.

Draeger’s ventilator product line for acute care includes the Evita Infinity V500 and Savina/Savina 300; for neonatal acute care, Babylog VN 500 and Draeger Babylog 8000 plus; for the transport care space, Oxylog 3000+ and 2000+; and finally, for non-invasive ventilation, the Carina. Recently, it incorporated additional ventilation modes and monitoring functions into the Savina 300 to provide customers with multiple therapy options.

“Frost & Sullivan believes that the company will outperform the overall market in the coming years, with the service and accessories business being major contributors to net sales,” said Frost & Sullivan Research Director Siddharth Saha. “Draeger has consistently maintained year-on-year profits across Europe and the United States, which is mostly a replacement market.”

Draeger employs a highly qualified and technically skilled team that maintains excellent relationships with end users through robust after-sales and product support services. Additionally, its strong brand name has made it the preferred partner of numerous distributors, and the company has strived to cement this advantage by offering online support and educational workshops for sales representatives and healthcare professionals.

The company varies its product line and services according to the regional and local needs of the market. Additionally, through a standard medibus communications protocol, Draeger ventilators, anesthesia machines, and monitors are compatible with third-party manufacturers of data management systems and other alarm systems.

“The company has solutions in the service and accessories business area that can be bundled with the ventilation devices,” noted Siddharth. “Draeger currently offers Service Connect 2.0, which is an advanced service portal providing online troubleshooting and diagnostics of its products. The open architecture of this service portal enables data exchange with customers.”

Draeger has been able to create and sustain its brand value over the years in Europe as well as in the United States, where it is difficult to earn significant profit margins in a replacement market. Overall, the company’s forethought in investing in technological innovations and its ability to maintain superior customer relationships set it apart from the competition.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in growth and customer value. It recognizes the superiority of the product/service as well as the overall customer, purchase, ownership and service experience offered, which has resulted in the recipient company seeing above-market growth and increased share of wallet. The award lauds the growth, diversification and sustainability strategies of the company.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About Draeger. Technology for Life®

Draeger is an international leader in the fields of medical and safety technology. Our products protect, support and save lives. Founded in 1889, Draeger generated revenues of around EUR 2.37 billion in 2013. The Draeger Group is currently present in more than 190 countries and has about 13,500 employees worldwide. Please visit www.draeger.com for more information.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:        Gain access to visionary innovation

Contact:

Frost & Sullivan

Draeger

Mireya Espinoza

Marion Varec

P: +1-210-247-3870

P: Tel +1-215-660-2186

F: +1-210-348-1003

E: marion.varec@draeger.com

E: mireya.espinoza@frost.com

http://www.twitter.com/DraegerNews

http://www.facebook.com/DraegerGlobal

http://www.youtube.com/USADraeger

Yew Bio-Pharm Applauds China State Forestry Administration’s Creation of Subsidies to Encourage Chinese Medicinal Herb Crops

HARBIN, China, October 30, 2014 /PRNewswire/ — Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (…

China Biologic to Report Third Quarter 2014 Financial Results

BEIJING, October 30, 2014 /PRNewswire/ — China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the C…

WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax

SHANGHAI, October 30, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, w…

Electronic Health Record Usability: CIOs Weigh In

— Frost & Sullivan: Enabling speedy and precise information retrieval is a priority for EHR vendors

MOUNTAIN VIEW, Calif., Oct. 30, 2014 /PRNewswire/ — Electronic health records uptake in the U.S. has accelerated dramatically as a result of government initiatives and the considerable resources – both capital and time – healthcare providers have invested over the past five years. Electronic health records have become the heart of health IT, and U.S. clinicians use them on a daily basis.

Frost & Sullivan (www.frost.com)

Frost & Sullivan (www.frost.com)

Frost & Sullivan’s newest health IT analysis, EHR Usability — CIOs Weigh in On What’s Needed to Improve Information Retrieval, finds that as the market matures and the volume of EHR data proliferates, ensuring reliable information retrieval from EHRs at the point-of-care will become a priority for healthcare providers.

For complimentary access to more information on this research, please visit: http://bit.ly/100bHee

In spite of significant progress in EHR adoption, the road is paved with pitfalls for many providers. Frequently highlighted customer pain points include:

  • Slow and inaccurate information retrieval from EHRs as well as difficulty in finding and reviewing data, both of which result in productivity losses for clinician end-users as well as potential risks to patient safety.
  • Inability to create targeted queries or easily access unstructured data such as clinician notes.
  • Time-consuming data entry tasks.

“U.S. regulatory authorities will take notice of the growing chorus of complaints about EHR usability, resulting in a push to devote more resources to solving this issue,” said Frost & Sullivan Connected Health Principal Analyst Nancy Fabozzi (@NancyFabozzi). “Further, the high levels of end-user frustration with usability present strong business opportunities for pioneering technology vendors.”

New vendors are emerging to address these challenges. Innovation will most likely come from companies with deep expertise in advanced enterprise search technology. Natural language processing (NLP) and visualization dashboards are the technologies most suitable to improve EHR usability. NLP can produce readable summaries of unstructured text, helping clinicians retrieve information needed for point-of-care decision making.

“Data visualization dashboards will enable end-users to quickly understand data trends, significantly enhancing ease-of-use by streamlining and organizing vast amounts of data,” added Fabozzi. “The ability to triangulate EHR data with data from other sources is also crucial to ensure access to the right medical information for healthcare providers.”

EHR Usability — CIOs Weigh in On What’s Needed to Improve Information Retrieval is a Customer Research study that is part of the Connected Health (http://www.connectedhealth.frost.com) Growth Partnership Service program. The research is based on an online survey of IT professionals working in US healthcare provider organizations. Administered in conjunction with the College of Health Information Management Executives (CHIME), the survey probes the key issues affecting access to structured and unstructured clinical data contained in EHRs. It discusses EHR spending and perceptions on ROI, core technology features needed to improve EHR search functionality, and additional technology solutions that users deploy to fill search functionality gaps.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on “the next big thing”
Register:         Gain access to visionary innovation

EHR Usability — CIOs Weigh in On What’s Needed to Improve Information Retrieval
NE62-48

Contact:
Jennifer Carson
Corporate Communications – North America
P: +1 210.247.2450
E: jennifer.carson@frost.com

Twitter: @Frost_Sullivan
Facebook: facebook.com/FrostandSullivan
Linkedin: http://linkd.in/1nL4auZ

http://www.frost.com

Logo – http://photos.prnasia.com/prnh/20141030/8521406407LOGO

TWi Pharmaceuticals Receives US FDA Approval on Generic Donepezil Hydrochloride Tablets USP, 23 mg, its fifth ANDA from US FDA

TAIPEI, October 30, 2014 /PRNewswire/ — TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Donep…

Protection Against Norovirus by Human-Milk-Oligosaccharides

Federal Ministry of Education and Research supports Development of Norovirus Prophylaxis by Jennewein Biotechnologie

RHEINBREITBACH, Germany, Oct. 30, 2014 /PRNewswire/ — Norovirus is the mos…

Lakeland Industries Provides Update on Business Activity Relating to Ebola Crisis

RONKONKOMA, New York, Oct. 30, 2014 /PRNewswire/ — Lakeland Industries, Inc. (NASDAQ: LAKE), a leading global manufacturer of industrial protective clothing for industry, municipalities, healthcare and to first responders on the federal, state and local levels, today provided the following update on recent business activities and corporate developments.

Logo – http://photos.prnewswire.com/prnh/20120611/NY21959LOGO

In anticipation of the worsening of the Ebola crisis, on September 12 the Company announced its intent to increase manufacturing capacity for specialty protective suits to be worn by healthcare workers and others being exposed to Ebola.  The Company has been experiencing significant interest globally for its ChemMAX® and MicroMAX® protective suit lines.   Manufacturing of select lines of these garments involves proprietary processes for specialized seam sealing, a far superior technology for protecting against viral hazards including infected body fluids than non-sealed products.  Lakeland accelerated its capital investment program for new machinery to accommodate higher levels of output and increased its spending for raw materials and the hiring and training of manufacturing personnel to address the increase in product demand. 

“Recent developments have enabled us to strengthen our balance sheet, increase forward cash flow from the elimination of interest service on expensive debt, and increase production capacity to contribute to the fight against the spread of Ebola which has led to a material improvement in our business,” said Christopher J. Ryan, CEO of Lakeland Industries, Inc.  “At the same time, we have also been experiencing an improvement in operating conditions for the balance of our business globally.  I am very proud of the way the worldwide team of Lakeland Industries has responded to the Ebola crisis while continuing to provide the highest level of service and quality garments to our traditional customers.”

Monthly production capacity for sealed seam ChemMAX and MicroMAX protective suit lines has increased by nearly 50% from August 2014, prior to Ebola-related product demand, to October 2014, and is on track for a 100% increase from that level by January 2015, with the ability for additional increases as needed.  Substantially all of the available production capacity in August 2014 had been allocated to purchases by the Company’s industrial customers (for non-Ebola related purposes).  The Company will continue to service its industrial customers who are dependent upon Lakeland to conduct their work safely.  The expanded capacity is necessary in order to meet obligations for both traditional customers as well as for protection against the spread of Ebola.

Through its direct sales force and numerous distribution partners throughout the world, Lakeland has secured new orders relating to the fight against the spread of Ebola.  Orders have been received from government agencies around the world as well as other public and private sector customers.  Certain of these contracts require weekly delivery guarantees or shipments through the first calendar quarter of 2015.  The aggregate of orders won by Lakeland that are believed to have resulted from the Ebola crisis amount to approximately 1 million suits with additional orders for other products, such as hoods, foot coverings and gloves.  Lakeland started shipping such orders only in October, which is the end of its fiscal 2015 third quarter reporting period.  The main impact from Ebola-related orders received to date will not be realized until the Company’s fiscal 2015 fourth quarter ended January 31, 2015. 

Furthermore, the Company is presently participating in bidding on numerous customer requests for additional quantities.  This additional amount may not reflect any of the global requirements for preparedness strategies to be implemented by governments and healthcare organizations resulting from the crisis in anticipation of future contagion scenarios.  It is important to note that product demand in crisis and emergency situations is very difficult to predict, and the Company makes no assurances of its ability to win additional business. 

Lakeland remains committed to participating in the fight against the spread of Ebola.  The Company’s global workforce and management team have been vigilant in responding to an unprecedented level of inquiries and in ramping production to meet delivery requirements.  For additional product information or to place an order, please visit www.lakeland.com or contact customer service:

United States at +1-256-350-3873
Argentina at +54-11-4897-5760
Brazil at +55-11-3613-3700
Canada at 800-489-9131
Chile at +562-551-8562
China at +010-6437-9226
India at +91-8447556757
Mexico at 800-837-9236
Russia at +7-495-775-72-64
UK at +44-14304-78140

About Lakeland Industries, Inc.:
Lakeland Industries, Inc. (NASDAQ: LAKE) manufactures and sells a comprehensive line of safety garments and accessories for the industrial protective clothing market.  The Company’s products are sold by a direct sales force and through independent sales representatives to a network of over 1,200 safety and mill supply distributors. These distributors in turn supply end user industrial customers such as chemical/petrochemical, automobile, steel, glass, construction, smelting, janitorial, pharmaceutical and high technology electronics manufacturers, as well as hospitals and laboratories. In addition, Lakeland supplies federal, state, and local government agencies, fire and police departments, airport crash rescue units, the Department of Defense, the Centers for Disease Control and Prevention, and many other federal and state agencies.  For more information concerning Lakeland, please visit the Company online at www.lakeland.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:  Forward-looking statements involve risks, uncertainties and assumptions as described from time to time in Press Releases and Forms 8-K, registration statements, quarterly and annual reports and other reports and filings filed with the Securities and Exchange Commission or made by management.  All statements, other than statements of historical facts, which address Lakeland’s expectations of sources or uses for capital or which express the Company’s expectation for the future with respect to financial performance or operating strategies can be identified as forward-looking statements.  As a result, there can be no assurance that Lakeland’s future results will not be materially different from those described herein as “believed,” “projected,” “planned,” “intended,” “anticipated,” “estimated” or “expected,” or other words which reflect the current view of the Company with respect to future events.  We caution readers that these forward-looking statements speak only as of the date hereof.  The Company hereby expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events conditions or circumstances on which such statement is based.

Any customers referenced or implied through reference in this press releases does not represent an endorsement of Lakeland Industries or its products.